Editor’s Note: The FDA guidance document for industry, “Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring” is available here.
From: Outsourcing-Pharma.com
The US Food and Drug Administration (FDA) has signed an agreement with CluePoints to “further explore” a data-driven approach to quality oversight in clinical trials.
Leave a Reply